A CMMS operating in a GxP environment without completed IQ/OQ/PQ protocols, a signed User Requirement Specification, and documented 21 CFR Part 11 controls exposes your facility to FDA 483 observations, Warning Letters, and consent decrees averaging $28 million in remediation cost. In 2024, FDA inspections cited inadequate computer system validation as a contributing factor in 61 percent of data integrity findings across drug manufacturing facilities. The validation documentation existed — in fragments. The failure was traceability: between validation evidence, system configuration, and the auditable record that demonstrates ongoing control. Oxmaint closes that gap. Book a demo to see how Oxmaint delivers a GAMP 5-aligned, pre-validated CMMS with full 21 CFR Part 11 compliance documentation for your facility.
Pharmaceutical CMMS validation requires a GAMP 5 category classification, signed URS, IQ/OQ/PQ protocols, 21 CFR Part 11 audit trail controls, and a maintained validation lifecycle. Oxmaint delivers all of this as a pre-built package — reducing validation cost by up to 70%, compressing time-to-validated-state from six months to eight weeks, and producing audit-ready documentation in under two hours for any FDA, EMA, or MHRA inspection.
The Four CSV Obligations Carrying the Highest Regulatory Risk
Each carries its own regulatory predicate, documentation standard, and enforcement consequence. Book a demo to see how Oxmaint addresses all four in a unified, audit-ready CSV program.
A CMMS managing GxP-critical maintenance — calibration records, PM for qualified equipment, change control for manufacturing assets — must be classified under GAMP 5 with a signed URS defining intended use, user roles, data criticality, and regulatory predicates. Without this, no downstream IQ/OQ/PQ activity is traceable to a defined validation scope. Oxmaint delivers a pre-built, pharma-specific URS template that anchors the entire CSV package from day one.
Each qualification phase requires pre-approved test scripts, executed evidence with actual results, deviation records, and authorized sign-off. Missing deviation closure and post-execution script modification are among the most common FDA 483 findings in CMMS packages. Oxmaint's pre-built IQ/OQ/PQ protocol library reduces scripting effort by over 70% and ensures every requirement traces directly to test pass evidence.
Electronic records in a pharma CMMS — calibration results, PM completions, work order approvals — must carry computer-generated, time-stamped, operator-identified audit trails that cannot be altered. FDA's 2018 Data Integrity Guidance and EU Annex 11 Clause 9 require these controls to be maintained for the life of the record. Oxmaint's Part 11 controls are native — audit trail, e-signature with meaning capture, and role-based access are active at deployment without custom development.
Validation is not a one-time event. System upgrades, configuration changes, and user role expansions all require documented change control impact assessments, with re-qualification executed where required. Without structured change control and a periodic review program, a validated CMMS drifts into an unvalidated state — typically discovered during an inspection. Oxmaint's integrated change control and periodic review workflow maintains validation status automatically through the system lifecycle.
Pre-Built CSV Package. Native Part 11 Controls. Audit-Ready from Day One.
Oxmaint delivers URS, IQ/OQ/PQ protocols, Part 11 controls documentation, and change control procedures — reducing validation effort by 70% and compressing time-to-validated-state from months to weeks. Book a demo to review the Oxmaint CSV package for your facility's regulatory scope.
Oxmaint vs Competing CMMS Platforms — Pharmaceutical CSV Capability
Most general-purpose CMMS platforms handle work orders. They do not handle GxP validation documentation, native Part 11 controls, or the lifecycle infrastructure pharmaceutical quality systems require.
| CSV Capability | Oxmaint | MaintainX | UpKeep | Fiix | Limble | IBM Maximo | Hippo CMMS | Infor EAM |
|---|---|---|---|---|---|---|---|---|
| Pre-built GAMP 5 URS & IQ/OQ/PQ package | Yes | No | No | No | No | Custom | No | Custom |
| Native 21 CFR Part 11 audit trail | Yes | No | No | Partial | No | Yes | No | Yes |
| Electronic signature with meaning capture | Yes | No | No | No | No | Yes | No | Partial |
| Validation lifecycle change control workflow | Yes | No | No | Partial | No | Yes | No | Partial |
| EU Annex 11 compliance documentation | Yes | No | No | No | No | Custom | No | Custom |
| FDA inspection-ready export in under 2 hours | Yes | Partial | Partial | Partial | Partial | Yes | Partial | Yes |
| URS-to-test-evidence traceability matrix | Yes | No | No | No | No | Yes | No | Partial |
| Deployment in weeks without validation consultant | Yes | Yes | Yes | Varies | Yes | No | Yes | No |
Measured Outcomes — Pharmaceutical Sites Using Oxmaint
Outcomes drawn from pharmaceutical manufacturing deployments where Oxmaint's pre-built CSV package replaced custom validation projects or unvalidated legacy CMMS systems.
From Unvalidated to FDA-Inspection-Ready — in 8 Weeks
Sites that deploy Oxmaint's pre-built CSV package close the validation documentation gap before the next inspection — not after a 483 observation forces a costly remediation program. Book a demo to see your current CSV gap identified in the first deployment session.
Platform Capabilities for Pharmaceutical Manufacturing
Classification record, URS, risk assessment, IQ/OQ/PQ protocol library, traceability matrix, and Validation Summary Report template — delivered at deployment, reducing validation effort by up to 70%.
Computer-generated, time-stamped, operator-identified audit trail native to every GxP record. Electronic signatures with meaning capture — no custom development, no third-party add-on.
Calibration schedules, out-of-tolerance alerts, NIST-traceable standard records, and certificate retention per instrument — full audit trail and e-sign-off on every calibration record.
Every system modification assessed for validation impact, routed for quality approval, and archived against the validation lifecycle file — validated state maintained through every upgrade automatically.
Annual periodic review records generated from system configuration data and change logs — validation status maintained without manual assembly outside the system.
Complete FDA, EMA, MHRA, or PMDA inspection-ready CSV package — URS, protocols, test evidence, traceability matrix, change records — exported in under 2 hours from Oxmaint.
Frequently Asked Questions
Close the Validation Gap Before the Next FDA Inspection
Pre-built GAMP 5 CSV package, native 21 CFR Part 11 audit trail, calibration management, and validation lifecycle change control — active in Oxmaint within 8 weeks, no external consultant required. Book a demo with your site validation lead and see the full IQ/OQ/PQ protocol library and Part 11 controls configured for your manufacturing scope.
